Clinical Trials and Special Patient Populations

Alex A. Adjei, MD, PhD

A native of Ghana, Dr. Alex A. Adjei attended the University of Ghana Medical School in Legon, Ghana. He obtained a doctorate in pharmacology at the University of Alberta in Edmonton, Alberta, Canada, and completed a residency in internal medicine at Howard University in Washington, D.C. He was a clinical and research fellow in oncology at Johns Hopkins School of Medicine and Hospital in Baltimore.

Adjei is the senior vice president of clinical research and the chairman of the department of medicine at the Roswell Park Cancer Institute in Buffalo, N.Y. His clinical and research programs focus on novel therapeutics for lung cancer and phase I clinical trials. He is also a member of the editorial board of CR magazine—the AACR's new magazine about people and progress in cancer.

Adjei has served on many National Cancer Institute committees. He was a member of the Lung Cancer Progress Review Group in 2000 and the Lung Cancer Concept Evaluating Panel from 1999 to 2002. He was an invited speaker and participant at the Colorectal and Lung Cancer State of the Science meetings. He is also a member of the Signal Transduction Working Group and the Clinical Research Review Committee study section of the National Center for Research Resources. He is on many journal editorial boards, including the Journal of Clinical Oncology, and is an associate editor of Current Drug Targets, Investigational New Drugs and the American Journal of Clinical Oncology. He has also played several service roles in the American Association for Cancer Research. He is a member of the Scientific Policy and Legislative Affairs Committee and the Minorities in Cancer Research Council, of which he was chair in 2003. He was co-chair of the program committee of the 2005 AACR Annual Meeting. Adjei’s clinical and research programs focus on novel therapeutics for cancer and early clinical trials (phase I and phase II).